Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17
about
Toxicity of amphetamines: an updateExpression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymesOptimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical PracticeFunctional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestaneDrug resistance in cancer: an overview.Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine.Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6(*)1 and CYP2D6(*)10 using cell-based models in vitro.The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity.Implementation of CYP2D6 genotyping in psychiatry.Pharmacogenetics and human genetic polymorphisms.Clinical issues in use of atypical antipsychotics for depressed patients.Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder?Omega-3 polyunsaturated fatty acids for major depressive disorder.Clinical applications of CYP genotyping in psychiatry.The Pharmacogenetics of Tramadol.Physiologically Based Pharmacokinetic (Pbpk) Model of the Cyp2d6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms In Vitro.Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro.Functional characterization of CYP2D6 novel allelic variants identified in the Chinese Han population.Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.Pinoline may be used as a probe for CYP2D6 activity.Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.Genotype-based quantitative prediction of drug exposure for drugs metabolized by CYP2D6.Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.Evaluation of tramadol and its main metabolites in horse plasma by high-performance liquid chromatography/fluorescence and liquid chromatography/electrospray ionization tandem mass spectrometry techniques.Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells.Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics.Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine.Effect of CYP2D6 variants on venlafaxine metabolism in vitro.Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects.Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study.Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
P2860
Q22252794-BED922A5-6640-4C54-9F28-902C6DC05811Q24320062-FFC6CDFB-87EA-43ED-B38A-AEE1E3E52F6BQ26797416-4BE9C104-2815-44FE-9FEF-DE55F98B1FE3Q33609979-DB3F627E-2DAC-40FE-BD2C-9DAC8CC8146EQ33777963-7F1833CF-E81C-4795-AA10-E9A470492C0AQ34437369-87760B26-A85B-401A-B2B1-AA0EA01A2FE8Q35718630-C1E3ADDC-D6BF-400C-B48D-47A225957135Q35852564-2C50A134-FE92-445D-8988-A626F65ECB1FQ36604262-6E6FE85F-6778-4CD2-8E8B-774C849CCA28Q36745814-8EF88AF3-847F-4245-BFDB-A5B4CCF03D46Q37178666-8688837D-0B38-464D-80A4-BE10F1640FF5Q37380190-77DD8DBF-2A15-42FE-8E8B-62C4F573598AQ37538787-2C280B03-7810-481C-8207-2EC986D97FD2Q37772183-4D58F850-8C2E-4D95-9B3E-30DF980924A2Q38109591-60F98CC8-5139-4A18-98D2-ED037D2BDF4BQ38109592-B8C8BACE-0A8A-4469-9A72-FD3A41BC80B9Q38148244-BEB60966-D465-43C9-95A7-A1F7E34B326BQ38247063-D11A2A67-7CE0-4B14-AD49-E39127D5F5E1Q38441114-7851697B-ADC5-438B-87D8-4723CAEA6222Q38599220-28E96DF6-3CA6-492A-8D70-1309D4F24B8FQ39219864-0AA5316F-DDAD-4AC6-AAD9-CAF310FBA6BBQ40136199-69875C0D-8357-4C8F-87E3-CE84B26CE417Q40604148-2A186EE5-FAA7-4411-9645-56CBF5F298FDQ40789842-87163FF0-4E82-49CB-A2A8-1C8D0C3E687AQ40877284-B234AA2F-F4F7-457D-88A0-CB85E21819E6Q41684510-4BD75F78-60DC-4EEE-9B21-A6761B53D356Q43026876-43860207-27D5-4241-87CC-F5F129713478Q43067616-D2F21B14-BD4C-4453-B9C9-B13002471F66Q43721876-48FADF34-3506-4AD5-BD5F-F83C53FEFF2DQ45759815-EBF9C492-1CF3-461E-A0EA-B4B5E7128A69Q46203485-A59B99DD-3400-42C0-94E0-2A61FA557172Q47736581-047C9A0D-1EAA-4C0C-A4BE-80647D383C6FQ52315457-3F2BC677-6EFF-4E62-BD17-8A95B8DB6AB5Q52765416-A6EA3374-D331-43BE-BA49-768965E759E0Q52821146-0DEB4C19-3975-43DA-95E8-11FBAAF8B277Q54193657-888B4F65-786E-4C0A-9E80-258D8C2E3268Q54349187-0F2E60BF-8903-4A55-A8CE-8508CE23BC2AQ54766895-A487ACD8-6C2B-4FED-9465-20229AA98C48Q55518076-6C9CAC9E-F4A2-4CFB-998C-9AC8273E8B03Q58771283-C911DC80-C084-4C1A-84A8-A5309FBB0533
P2860
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Comparative metabolic capabili ...... D6.1, CYP2D6.10, and CYP2D6.17
@ast
Comparative metabolic capabili ...... D6.1, CYP2D6.10, and CYP2D6.17
@en
Comparative metabolic capabili ...... D6.1, CYP2D6.10, and CYP2D6.17
@nl
type
label
Comparative metabolic capabili ...... D6.1, CYP2D6.10, and CYP2D6.17
@ast
Comparative metabolic capabili ...... D6.1, CYP2D6.10, and CYP2D6.17
@en
Comparative metabolic capabili ...... D6.1, CYP2D6.10, and CYP2D6.17
@nl
prefLabel
Comparative metabolic capabili ...... D6.1, CYP2D6.10, and CYP2D6.17
@ast
Comparative metabolic capabili ...... D6.1, CYP2D6.10, and CYP2D6.17
@en
Comparative metabolic capabili ...... D6.1, CYP2D6.10, and CYP2D6.17
@nl
P2093
P356
P1476
Comparative metabolic capabili ...... D6.1, CYP2D6.10, and CYP2D6.17
@en
P2093
Hongwu Shen
Minxia M He
Steven A Wrighton
P304
P356
10.1124/DMD.107.015354
P407
P50
P577
2007-04-30T00:00:00Z